Astellas Pharma and Sangamo Therapeutics have signed a licence agreement for a neurotropic adeno-associated virus (AAV) ...

The agreement grants the Japanese pharma the worldwide license to initially use Sangamo's proprietary neurotropic ...

Astellas signs license agreement with Sangamo Therapeutics to deliver genomic medicines for neurological diseases: Tokyo and Richmond, Calif Saturday, December 21, 2024, 10:00 Hrs ...

For central nervous system (CNS) applications, attempts are being made to deliver AAV gene therapy directly to the brain parenchyma or the cerebrospinal fluid (CSF) space by intra-cisterna magna ...

Astellas Pharma partners with Sangamo Therapeutics to license STAC-BBB, a neurotropic AAV capsid for neurological disease ...

(RTTNews) - Astellas Pharma Inc. (ALPMY) Thursday said it has signed an agreement with Sangamo Therapeutics, Inc. (SGMO) to leverage Sangamo's proprietary neurotropic adeno-associated virus (AAV) ...

“Astellas”), today announced they have entered into a license agreement allowing Astellas to leverage Sangamo’s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC ...

Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced they have entered into a ...